Abstract |
This open label pilot study evaluated the safety and efficacy of the oral 5-HT3 receptor antagonist granisetron for prophylaxis of delayed chemotherapy-induced nausea and vomiting (CINV) in 30 patients with advanced or recurrent colorectal cancer. Patients were studied during two cycles of a 5-week regimen with irinotecan (CPT-11) and UFT. Patients received prophylactic anti-emetic therapy that included intravenous granisetron. If Grade 1 or higher severity gastrointestinal symptoms occurred during 6 days after CPT-11 administration in Cycle 1, then oral granisetron was administered daily for the following 5 days of CPT-11 in Cycle 2. Sixteen patients (53.3%) experienced delayed CINV in Cycle 1. The incidence of Grade 2 or higher vomiting was 32.1% and 27.7% in Cycles 1 and 2 in males (P = 0.554) respectively, and 54.6% and 32.4% in females (P = 0.001) respectively. Granisetron is effective against delayed Grade 2 or higher vomiting induced by CPT-11/UFT in female patients, although granisetron alone may not sufficiently control nausea induced by this regimen.
|
Authors | M Ikeda, M Yasui, H Fukunaga, I Seshimo, O Takayama, M Ikenaga, H Yamamoto, M Ohue, M Sekimoto, M Monden |
Journal | European journal of cancer care
(Eur J Cancer Care (Engl))
Vol. 14
Issue 5
Pg. 435-9
(Dec 2005)
ISSN: 0961-5423 [Print] England |
PMID | 16274464
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antiemetics
- Irinotecan
- Granisetron
- Camptothecin
|
Topics |
- Administration, Oral
- Adult
- Aged
- Antiemetics
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Camptothecin
(adverse effects, analogs & derivatives)
- Colorectal Neoplasms
(drug therapy)
- Female
- Granisetron
(therapeutic use)
- Humans
- Irinotecan
- Male
- Middle Aged
- Nausea
(chemically induced, drug therapy)
- Pilot Projects
- Vomiting
(chemically induced, drug therapy)
|